Infusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab and Apatinib for Advanced HCC

This study is comparing two chemotherapy delivery methods for advanced liver cancer (hepatocellular carcinoma): standard intravenous FOLFOX chemotherapy versus HAIC-FOLFOX (where the chemotherapy is delivered directly into the liver's blood supply through a catheter). Both groups also receive camrelizumab (immunotherapy) and apatinib (a drug that blocks tumor blood vessel growth). **You may be eligible if...** - You are 18 to 75 years old - You have been diagnosed with primary liver cancer (hepatocellular carcinoma) at advanced stage (BCLC stage C) - Your liver function is rated Child-Pugh A or B (meaning the liver is still functioning reasonably well) - You have at least one measurable tumor - You have not yet received first-line targeted drug treatments such as sorafenib - You are in generally good health (ECOG 0-2) with expected survival of at least 12 weeks - If you have hepatitis B or C, you are receiving antiviral treatment **You may NOT be eligible if...** - You have received prior first-line systemic treatment for liver cancer - Your blood counts or organ function do not meet required levels - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.